BridgeBio reports encaleret raised bone turnover in Phase 3 CALIBRATE, 100% of participants report improvement in at least one ADH1 symptom

BridgeBio reported that its encaleret raised bone turnover in the Phase 3 CALIBRATE study, with 100% of participants reporting improvement in at least one ADH1 symptom versus 46% on standard of care.

Detected & updated continuously · Source: Nebula